595 related articles for article (PubMed ID: 25885818)
1. Cost-effectiveness of active monitoring versus antidepressants for major depression in primary health care: a 12-month non-randomized controlled trial (INFAP study).
Rubio-Valera M; Beneitez I; Peñarrubia-María MT; Luciano JV; Mendive JM; McCrone P; Knapp M; Sabés-Figuera R; Kocyan K; García-Campayo J; Serrano-Blanco A
BMC Psychiatry; 2015 Mar; 15():63. PubMed ID: 25885818
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of antidepressants versus active monitoring for mild-to-moderate major depressive disorder: a multisite non-randomized-controlled trial in primary care (INFAP study).
Rubio-Valera M; Peñarrubia-María MT; Iglesias-González M; Knapp M; McCrone P; Roig M; Sabes-Figuera R; Luciano JV; Mendive JM; Murrugara-Centurión AG; Alonso J; Serrano-Blanco A
Eur J Health Econ; 2019 Jul; 20(5):703-713. PubMed ID: 30725226
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness of watchful waiting versus antidepressants for patients diagnosed of mild to moderate depression in primary care: A 12-month pragmatic clinical trial (INFAP study).
Iglesias-González M; Aznar-Lou I; Peñarrubia-María MT; Gil-Girbau M; Fernández-Vergel R; Alonso J; Serrano-Blanco A; Rubio-Valera M
Eur Psychiatry; 2018 Sep; 53():66-73. PubMed ID: 29957370
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic accuracy and treatment approach to depression in primary care: predictive factors.
Aznar-Lou I; Iglesias-González M; Rubio-Valera M; Peñarrubia-Maria MT; Mendive JM; Murrugarra-Centurión AG; Gil-Girbau M; González-Suñer L; Peuters C; Serrano-Blanco A
Fam Pract; 2019 Jan; 36(1):3-11. PubMed ID: 30423158
[TBL] [Abstract][Full Text] [Related]
5. CASPER plus (CollAborative care in Screen-Positive EldeRs with major depressive disorder): study protocol for a randomised controlled trial.
Overend K; Lewis H; Bailey D; Bosanquet K; Chew-Graham C; Ekers D; Gascoyne S; Hems D; Holmes J; Keding A; McMillan D; Meer S; Meredith J; Mitchell N; Nutbrown S; Parrott S; Richards D; Traviss G; Trépel D; Woodhouse R; Gilbody S
Trials; 2014 Nov; 15(1):451. PubMed ID: 25409776
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of usual general practitioner care with or without antidepressant medication for patients with minor or mild-major depression.
Bosmans JE; Hermens ML; de Bruijne MC; van Hout HP; Terluin B; Bouter LM; Stalman WA; van Tulder MW
J Affect Disord; 2008 Nov; 111(1):106-12. PubMed ID: 18342952
[TBL] [Abstract][Full Text] [Related]
7. Economic Evaluation of an Internet-Based Preventive Cognitive Therapy With Minimal Therapist Support for Recurrent Depression: Randomized Controlled Trial.
Klein NS; Bockting CL; Wijnen B; Kok GD; van Valen E; Riper H; Cuijpers P; Dekker J; van der Heiden C; Burger H; Smit F
J Med Internet Res; 2018 Nov; 20(11):e10437. PubMed ID: 30478021
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness and cost-effectiveness of a guided Internet- and mobile-based intervention for the indicated prevention of major depression in patients with chronic back pain-study protocol of the PROD-BP multicenter pragmatic RCT.
Sander L; Paganini S; Lin J; Schlicker S; Ebert DD; Buntrock C; Baumeister H
BMC Psychiatry; 2017 Jan; 17(1):36. PubMed ID: 28109247
[TBL] [Abstract][Full Text] [Related]
9. The clinical and cost effectiveness of cognitive behavioural therapy plus treatment as usual for the treatment of depression in advanced cancer (CanTalk): study protocol for a randomised controlled trial.
Serfaty M; King M; Nazareth I; Tookman A; Wood J; Gola A; Aspden T; Mannix K; Davis S; Moorey S; Jones L
Trials; 2016 Feb; 17(1):113. PubMed ID: 26926910
[TBL] [Abstract][Full Text] [Related]
10. Cost and Outcome of Behavioural Activation versus Cognitive Behavioural Therapy for Depression (COBRA): a randomised, controlled, non-inferiority trial.
Richards DA; Ekers D; McMillan D; Taylor RS; Byford S; Warren FC; Barrett B; Farrand PA; Gilbody S; Kuyken W; O'Mahen H; Watkins ER; Wright KA; Hollon SD; Reed N; Rhodes S; Fletcher E; Finning K
Lancet; 2016 Aug; 388(10047):871-80. PubMed ID: 27461440
[TBL] [Abstract][Full Text] [Related]
11. Community pharmacist intervention in depressed primary care patients (PRODEFAR study): randomized controlled trial protocol.
Rubio-Valera M; Serrano-Blanco A; Travé P; Peñarrubia-María MT; Ruiz M; Pujol MM
BMC Public Health; 2009 Aug; 9():284. PubMed ID: 19656386
[TBL] [Abstract][Full Text] [Related]
12. European COMPARative Effectiveness research on blended Depression treatment versus treatment-as-usual (E-COMPARED): study protocol for a randomized controlled, non-inferiority trial in eight European countries.
Kleiboer A; Smit J; Bosmans J; Ruwaard J; Andersson G; Topooco N; Berger T; Krieger T; Botella C; Baños R; Chevreul K; Araya R; Cerga-Pashoja A; Cieślak R; Rogala A; Vis C; Draisma S; van Schaik A; Kemmeren L; Ebert D; Berking M; Funk B; Cuijpers P; Riper H
Trials; 2016 Aug; 17(1):387. PubMed ID: 27488181
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of collaborative care for chronically ill patients with comorbid depressive disorder in the general hospital setting, a randomised controlled trial.
Horn EK; van Benthem TB; Hakkaart-van Roijen L; van Marwijk HW; Beekman AT; Rutten FF; van der Feltz-Cornelis CM
BMC Health Serv Res; 2007 Feb; 7():28. PubMed ID: 17324283
[TBL] [Abstract][Full Text] [Related]
14. Protocol for the THREAD (THREshold for AntiDepressants) study: a randomised controlled trial to determine the clinical and cost-effectiveness of antidepressants plus supportive care, versus supportive care alone, for mild to moderate depression in UK general practice.
Chatwin J; Kendrick T;
BMC Fam Pract; 2007 Jan; 8():2. PubMed ID: 17204136
[TBL] [Abstract][Full Text] [Related]
15. Investigating the (cost-) effectiveness of attention bias modification (ABM) for outpatients with major depressive disorder (MDD): a randomized controlled trial protocol.
Ferrari GR; Becker ES; Smit F; Rinck M; Spijker J
BMC Psychiatry; 2016 Nov; 16(1):370. PubMed ID: 27809880
[TBL] [Abstract][Full Text] [Related]
16. Novel Augmentation Strategies in Major Depression.
Martiny K
Dan Med J; 2017 Apr; 64(4):. PubMed ID: 28385173
[TBL] [Abstract][Full Text] [Related]
17. Cost effectiveness of a pharmacy-based coaching programme to improve adherence to antidepressants.
Bosmans JE; Brook OH; van Hout HP; de Bruijne MC; Nieuwenhuyse H; Bouter LM; Stalman WA; van Tulder MW
Pharmacoeconomics; 2007; 25(1):25-37. PubMed ID: 17192116
[TBL] [Abstract][Full Text] [Related]
18. One size fits some: the impact of patient treatment attitudes on the cost-effectiveness of a depression primary-care intervention.
Pyne JM; Rost KM; Farahati F; Tripathi SP; Smith J; Williams DK; Fortney J; Coyne JC
Psychol Med; 2005 Jun; 35(6):839-54. PubMed ID: 15997604
[TBL] [Abstract][Full Text] [Related]
19. Escitalopram and duloxetine in major depressive disorder: a pharmacoeconomic comparison using UK cost data.
Wade AG; Fernández JL; François C; Hansen K; Danchenko N; Despiegel N
Pharmacoeconomics; 2008; 26(11):969-81. PubMed ID: 18850765
[TBL] [Abstract][Full Text] [Related]
20. Cost and outcome of behavioural activation versus cognitive behaviour therapy for depression (COBRA): study protocol for a randomised controlled trial.
Rhodes S; Richards DA; Ekers D; McMillan D; Byford S; Farrand PA; Gilbody S; Hollon SD; Kuyken W; Martell C; O'Mahen HA; O'Neill E; Reed N; Taylor RS; Watkins ER; Wright KA
Trials; 2014 Jan; 15():29. PubMed ID: 24447460
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
